Asia Pacific Spine Biologics Market Size, Share, Growth and Forecast, 2025-2035

Aging patients and fusion volumes anchor bone graft demand

The Asia Pacific spine biologics market was valued at USD 439.5 million in 2025 and is projected to increase from USD 469.0 million in 2026 to USD 834.0 million by 2035, registering a CAGR of 6.60% during 2026–2035. Demand comes from older patients who need lumbar and cervical fusion, hospitals that buy graft material to help bone heal across fused levels, and surgeons who want less reliance on bone taken from the hip. Mainland China held the largest sub-regional share, 53.9% in 2025, because national tenders have cut spinal implant prices and widened access to fusion surgery. India and Southeast Asia is the fastest-growing sub-region at 8.08% a year, as new hospital bone banks and public insurance for older adults bring more patients to surgery. Japan approved a peptide-based bone regeneration material on Feb. 13, 2026, after a lumbar fusion study, which shows how new graft types are reaching the region.

Which bone graft products does the regional estimate cover?

The estimate measures spending on graft materials used to achieve bone fusion in spinal surgery across Asia Pacific. It covers allograft products, synthetic ceramic grafts, growth factor grafts and cellular or combination products bought by hospitals, ambulatory surgery centers and specialty spine clinics. Values are measured at the price paid by the provider, whether through direct contracts, specialist distributors or public tenders.

The estimate excludes screws, rods, cages and other spinal implants, as well as bone growth stimulators and the patient's own bone harvested during surgery. The value chain runs from tissue banks and material makers through device companies and distributors to the hospitals and clinics that treat patients in Mainland China, Japan and South Korea, India and Southeast Asia, and Oceania and Remaining Asia Pacific.

Synthetic grafts lead, growth factor grafts grow fastest

Why do synthetic grafts lead product demand?

Based on product type, the market is categorized into allograft products, synthetic graft products, growth factor graft products and cellular and combination graft products. Synthetic Graft Products led with a 40.0% share of 2025 value, because ceramic grafts are easy to store and avoid the donor tissue shortages common in the region. Growth Factor Graft Products grow fastest at 7.99% a year, as Korean protein-based grafts gain distribution partners.

How do hospitals shape care setting demand?

Based on care setting, the market is categorized into hospitals, ambulatory surgery centers and specialty spine clinics. Hospitals led with a 78.0% share of 2025 value, because most fusion surgery in China, India and Japan still takes place in large inpatient centers. Ambulatory Surgery Centers grow fastest at 8.53% a year, as shorter, less invasive procedures move into day surgery units.

Why do degenerative conditions dominate case volumes?

Based on disease area, the market is categorized into degenerative spinal conditions, spinal deformity and revision and reconstructive conditions. Degenerative Spinal Conditions led with a 68.0% share of 2025 value, because stenosis and disc disease drive most fusion cases in older adults. Revision and Reconstructive Conditions grow fastest at 6.95% a year, since repeat surgery and failed fusions need more graft material per case.

How do specialist distributors lead sales?

Based on sales channel, the market is categorized into direct manufacturer contracts, specialist distributor sales and tender-led supply. Specialist Distributor Sales led with a 41.0% share of 2025 value, because device makers rely on local partners to reach hospitals across many countries. Tender-Led Supply grows fastest at 7.09% a year, as public buyers in China extend tenders to more surgical consumables.

Older patients, matrix access and distributors lift demand

How does age-related spine disease widen surgical demand?

An older population brings more disc degeneration and stenosis, which raises the number of patients who qualify for fusion surgery. People aged 65 and over made up 29.8% of Japan's population, 19.3% of South Korea's and 17.7% of Australia's in 2024, according to World Bank data. China had more than 220.2 million people aged 65 and over at the end of 2024, or about 15.6% of its population. India also issued more than 9.3 million Ayushman Vay Vandana cards by Oct. 31, 2025, which give people aged 70 and over Rs 500,000 of hospital cover each year. As a result, degenerative spinal conditions hold a 68.0% share of 2025 value.

Why does established demineralized matrix access matter?

Surgeons need graft options that are approved and stocked locally, and demineralized bone matrix gives them a proven alternative to bone taken from the hip. Japan's regulator cleared Medtronic's Grafton demineralized bone matrix in August 2018, and the company launched it in February 2019 as the first such product in Japan, according to a Medtronic release that cited use in more than 1.5 million procedures worldwide. The release also described Japan as the second-largest market for spinal medical devices in the world. In India, the national tissue bank at Safdarjung Hospital supplies freeze-dried bone allografts to surgeons. In turn, locally approved matrix and synthetic grafts support Japan and South Korea, which hold 17.9% of 2025 value.

Download Free Sample

How do specialist distributors and partnerships extend reach?

Device makers sell bone graft products through local partners that already serve spine surgeons, which extends reach across many health systems. Johnson & Johnson signed an exclusive deal with CGBIO in February 2025 to distribute the NOVOSIS growth factor graft in Korea, Taiwan, Thailand, India, Hong Kong and Macau, according to a DePuy Synthes release. DePuy Synthes then added exclusive rights for Australia on May 26, 2026. In Australia and New Zealand, the distributor LifeHealthcare kept serving hospitals when Stryker's spinal implants business moved to VB Spine in July 2025. As a result, specialist distributor sales lead the channel mix with a 41.0% share.

Why does centralized purchasing in China lift case volumes?

National tenders have cut the price of spinal implants in China, which lowers the cost of surgery and brings more patients to fusion. The national tender for spinal consumables in September 2022 cut prices by an average of 84%, according to China Daily. The same report said posterior thoracolumbar fixation sets fell from 33,000 yuan to about 4,500 yuan on average. Jiemian reported that 6,426 medical institutions submitted demand for about 1.21 million sets in that tender. In turn, lower implant costs widen access to fusion surgery in public hospitals, and tender-led supply grows at 7.09% a year.

Growth factor grafts, peptide gels and bone banks emerge

How is the shift to growth factor grafts changing supply?

Korean developers are bringing protein-based grafts to the region, which gives surgeons an option that actively signals bone growth. CGBIO said in April 2025 that its NOVOSIS Putty, which releases rhBMP-2 from a ceramic carrier, had completed phase 1 and two trials in Japan, according to The Korea Herald. The same product won U.S. approval for a pivotal spinal fusion trial that month. CGBIO also signed a supply deal with a Shanghai orthopedic company in December 2025 that targets Chinese approval of NOVOSIS by the third quarter of 2027, according to The Asia Business Daily. As a result, growth factor graft products grow fastest at 7.99% a year.

Why are peptide and synthetic regeneration materials on the rise?

Japanese makers are developing synthetic materials that guide new bone without donor tissue, which suits a country with limited allograft supply and a strong local materials industry. Japan approved Menicon's Verte absorbable bone regeneration material on Feb. 13, 2026, according to a PMDA review summary. The supporting study used the peptide gel in posterior lumbar interbody fusion and reported a 95.12% bone union rate at 12 months. The review compared that rate with historical results for beta-tricalcium phosphate combined with the patient's own bone, a common synthetic bone graft substitute option. In turn, synthetic graft products keep a 40.0% share of product demand, and new local approvals strengthen that lead.

Download Free Sample

Can hospital bone banks open new allograft supply in India?

New bone banks and wider insurance for older adults are creating fresh allograft supply and demand in India. CK Birla Hospitals opened a bone bank at CMRI Kolkata on Dec. 1, 2025, which it described as the first in Eastern India, according to Medical Dialogues. The bank processes structural blocks, morselized grafts and cancellous chips for spinal fusion, tumor and deformity surgery. The national tissue bank at Safdarjung Hospital in New Delhi also registers and trains other tissue banks. Under Ayushman Vay Vandana, 789,000 hospital admissions worth Rs 17.41 billion were authorized by Oct. 31, 2025, according to Health Ministry data. As a result, allograft products gain new local supply in a sub-region that grows fastest in the forecast.

Is there room for growth in private Oceania spine care?

Private hospitals perform most fusion surgery in Australia, which opens room for premium graft products that private health insurers and hospital groups fund. Private hospitals accounted for 83% of 14,608 lumbar spinal fusion admissions from 2015-16 to 2017-18, according to the Australian Commission on Safety and Quality in Health Care. DePuy Synthes won exclusive Australian rights to the NOVOSIS graft on May 26, 2026, pending local clinical data and approval. Globus Medical also said in its 2025 annual report that a significant part of its foreign revenue comes from Japan and Australia. In turn, Oceania and Remaining Asia Pacific grows at 5.88% a year.

Tender prices, tissue supply and evidence gaps slow uptake

How do tender prices squeeze graft margins?

Public tenders in China have pushed implant prices down sharply, which puts pressure on the price of every product used in the same surgery. Hospitals that buy low-cost implant sets often expect cheaper graft material as well. As a result, suppliers of premium matrices and protein grafts struggle to win volume in public hospitals. Companies respond by offering lower-cost synthetic ranges and by focusing on private hospitals and complex cases.

Why does limited donor tissue restrict allograft supply?

Many countries in the region have few licensed tissue banks, which limits the supply of donor bone for spinal surgery. India's national tissue bank opened only in 2017, and private banks such as the one at CMRI Kolkata opened in 2025. In turn, surgeons often rely on bone taken from the patient or on imported products. Tissue banks respond with new screening and processing standards, but building donor programs takes years.

How do evidence demands slow new graft approvals?

Regulators ask for clinical data before approving new graft types, which delays launches across the region. Menicon needed a multicenter lumbar fusion study in Japan before the regulator would approve its Verte peptide material. CGBIO also expects Chinese approval of NOVOSIS only by the third quarter of 2027. As a result, companies must fund trials in several countries before sales begin, which favors larger firms with deep clinical teams.

Why does fragmented regulation raise market entry costs?

Each country in the region sets its own approval rules for tissue and device products, which raises costs for companies that sell across borders. Globus Medical noted in its 2025 annual report that Japan requires separate regional filings, while Australia and India accept some foreign approvals. In turn, smaller graft makers enter fewer markets in the region each year. Companies respond by signing local distribution deals with partners that already hold licenses.

Mainland China leads, India and Southeast Asia grow fastest

Why does Mainland China hold the largest share?

China had about 310.3 million people aged 60 and over at the end of 2024, according to the State Council, which gives it the largest pool of fusion patients in the region. As a result, Mainland China held a 53.9% share of 2025 value and grows at 6.48% a year. National tenders also cut spinal implant prices by an average of 84%, which brought more patients to surgery in public hospitals.

Why are India and Southeast Asia growing fastest?

Access to spinal surgery is widening from a low base in India, Thailand, Vietnam and Indonesia, where older populations are still small but rising. India and Southeast Asia held a 22.2% share of 2025 value and grow at 8.08% a year. India gives people aged 70 and over Rs 500,000 of hospital cover a year under Ayushman Vay Vandana. Hospital bone banks and the NOVOSIS distribution deal for India and Thailand also add new graft options, while regional demand for thoracolumbar fusion implants rises.

Download Free Sample

How do Japan and South Korea support premium graft demand?

People aged 65 and over made up 29.8% of Japan's population and 19.3% of South Korea's in 2024, and both countries run well-funded hospitals. As a result, Japan and South Korea held a 17.9% share of 2025 value and grow at 5.18% a year. Japanese hospitals can now choose from demineralized matrix, ceramic and peptide grafts, while Korean developer CGBIO supplies growth factor grafts and completed early trials in Japan.

What shapes demand in Oceania and the remaining region?

Oceania and Remaining Asia Pacific held a 6.0% share of 2025 value and grows at 5.88% a year, because private hospitals in Australia fund most spinal fusion surgery. Private hospitals handled 83% of lumbar fusion admissions in the latest national atlas. VB Spine took over Stryker's spinal implants business in Australia and New Zealand in July 2025.

Download Free Sample

Graft approvals, supply deals and new bone banks since 2025

Ceramic scaffolds, matrices and protein carriers shape use

• Osteoconductive scaffolds such as beta-tricalcium phosphate and hydroxyapatite give new bone a frame to grow on, which suits hospitals that lack donor tissue.
• Osteoinductive matrices such as demineralized bone matrix contain natural proteins that signal bone growth, which helps surgeons extend limited local bone.
• Protein carriers release rhBMP-2 slowly from a ceramic base, which aims to support fusion while limiting unwanted bone growth outside the target area.
• Self-assembling peptide gels form a scaffold once implanted, which lets new bone form in fusion procedures without relying on donor tissue.

Device makers compete through graft range and partners

Competition in spine biologics combines global device makers with Korean, Japanese and Chinese graft developers and local tissue banks. Medtronic launched the Grafton demineralized bone matrix in Japan in 2019 as the first product of its kind there. DePuy Synthes, part of Johnson & Johnson, holds exclusive rights to distribute CGBIO's NOVOSIS growth factor graft in six Asian markets and in Australia. Globus Medical sells allograft and synthetic biologics and earns a significant part of its foreign revenue in Japan and Australia. Highridge Medical counts Japan as its second-largest market, according to a September 2025 interview with its chief executive published by H.I.G. Capital, the private equity firm that owns the company today. Stryker moved its spinal implants business in Australia and New Zealand to VB Spine in July 2025. Companies compete on product range, clinical data and local distribution partners that reach surgeons.

Companies profiled and their roles in this market

Credence Research view on regional bone graft demand

Credence Research's view is that spine biologics demand in Asia Pacific will grow steadily because aging populations need more fusion surgery and new graft types are reaching the region. Synthetic grafts stay the largest product group, while growth factor grafts grow fastest as Korean developers sign distribution deals. Mainland China keeps the largest share, and India and Southeast Asia grow fastest as insurance and bone banks widen access. However, tender pricing and evidence demands will slow premium products. Suppliers that pair clinical data with strong local partners should gain share fastest.

How the regional bone graft estimate was built

The report uses 2025 as the base year on a calendar basis, and market values come from the Credence Research model. That model combines surgical volumes, tender demand, population aging statistics, product approvals and company information on distribution and product range. Segment splits and sub-regional growth rates are Credence Research estimates, while sub-regional shares follow the client-defined split. Sources used are official statistics, regulator documents, company releases, annual reports and news reports, and no interviews or surveys were used.

Aging, new graft types and partners carry growth to 2035

Regional spine biologics value is expected to reach USD 834.0 million by 2035, a 6.60% CAGR during 2026–2035, as more older patients undergo fusion surgery. Growth should be steady through 2030 while protein-based and peptide grafts complete approvals in China, Japan and Australia. After that, wider bone bank networks and insurance for older adults in India should add volume. Faster approvals of protein and peptide grafts would raise this outlook, while deeper tender price cuts in China or slower tissue bank growth would lower it.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.